Small-molecule modulators of c-Myc/Max and Max/Max interactions.

The transcription factor c-Myc is overexpressed in many tumors in human beings and has been identified as a highly promising target for cancer therapy. Most biological functions of c-Myc require heterodimerization with its activation partner Max. Inhibition of the protein-protein interactions between c-Myc and Max by small molecules has been shown to be a feasible and powerful approach toward the inhibition of c-Myc functions. More recently, stabilization of Max homodimers to reduce the amount of Max available for activating c-Myc has also been demonstrated to counteract Myc activity. This review summarizes our current knowledge on small organic molecules that inhibit c-Myc by modulating protein-protein interactions relevant for the biological function of this important oncoprotein.

[1]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Kräutler,et al.  Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. , 2001, Journal of molecular biology.

[3]  T. Berg.  Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[4]  P. Vogt,et al.  A credit-card library approach for disrupting protein-protein interactions. , 2006, Bioorganic & medicinal chemistry.

[5]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[6]  E. Rowinsky.  Paclitaxel pharmacology and other tumor types. , 1997, Seminars in oncology.

[7]  S. Pelengaris,et al.  The many faces of c-MYC. , 2003, Archives of biochemistry and biophysics.

[8]  T. Berg.  Inhibition of transcription factors with small organic molecules. , 2008, Current opinion in chemical biology.

[9]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[10]  I. Bahar,et al.  Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. , 2009, Journal of medicinal chemistry.

[11]  Dirk Eick,et al.  Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. , 2006, Chemistry & biology.

[12]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[13]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[14]  Tatjana Marinkovic,et al.  Reversible lymphomagenesis in conditionally c‐MYC expressing mice , 2004, International journal of cancer.

[15]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[16]  Arthur J. Olson,et al.  Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function , 2009, Molecular Pharmacology.

[17]  Martin Würtele,et al.  Structural view of a fungal toxin acting on a 14‐3‐3 regulatory complex , 2003, The EMBO journal.

[18]  Landon R. Whitby,et al.  Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. , 2009, Bioorganic & medicinal chemistry letters.

[19]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[20]  T. Berg.  Signal Transducers and Activators of Transcription as Targets for Small Organic Molecules , 2008, ChemBioChem.

[21]  Bianca Sperl,et al.  Selective Inhibition of c‐Myc/Max Dimerization by a Pyrazolo[1,5‐a]pyrimidine , 2007, ChemMedChem.

[22]  J. Acker,et al.  Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.

[23]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[24]  Ariele Viacava Follis,et al.  Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. , 2009, Journal of the American Chemical Society.

[25]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[26]  P. Gallant,et al.  Max-independent functions of Myc in Drosophila melanogaster , 2008, Nature Genetics.

[27]  R. Eisenman,et al.  Myc's broad reach. , 2008, Genes & development.

[28]  Stephen K. Burley,et al.  Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain , 1993, Nature.

[29]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[30]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[31]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[32]  Peter T Lansbury,et al.  Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Boger,et al.  Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. , 2008, Oncology reports.

[34]  P. Gallant,et al.  Myc’s secret life without Max , 2009, Cell cycle.

[35]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[36]  Ariele Viacava Follis,et al.  Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. , 2008, Chemistry & biology.

[37]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.